COVID-19 is an emerging, rapidly evolving siituation.

What people with cancer should know:

Guidance for cancer researchers:

Get the latest public health information from CDC:

Get the latest research information from NIH:

CPTAC Team Releases Targeted Proteomic Assays for Ovarian Cancer

Pacific Northwest National Laboratory (PNNL) investigators in the Clinical Proteomic Tumor Analysis Consortium (CPTAC) of the National Cancer Institute (NCI), announces the public release of 98 targeted mass spectrometry-based assays for ovarian cancer research studies.  Chosen based on proteogenomic observations from the recently published multi-institutional collaborative project between PNNL and Johns Hopkins University that comprehensively examined the collections of proteins in the tumors of ovarian cancer patients (highlighted in a paper in Cell), these selected reaction monitoring (SRM) assays covering 70 proteins in high grade serous ovarian carcinomas represent a first set of ovarian cancer targeted proteomic assays that are available to the community and just published in the journal Scientific Data.

Targeted proteomic assay methods, such as SRM and parallel reaction monitoring (PRM), are an excellent tool for protein quantification in basic and translational research applications.  These 98 SRM assays fully adhere to the standards and guidelines developed by CPTAC and meet the minimum characterization requirements for entry to the CPTAC Assay Portal.  This community web-based repository for quantitative targeted proteomic assays, was highlighted in a paper in Nature Methods and currently consists of greater than 1500 “fit-for-purpose” targeted proteomic assays and serves as a public resource of methodologies and data related to cancer associated proteins and peptides.

For more information, click Scientific Data.